MARKET

PVLA

PVLA

Palvella Therapeutics Inc
NASDAQ
119.86
-3.60
-2.92%
Closed 16:48 04/06 EDT
OPEN
123.17
PREV CLOSE
123.46
HIGH
124.93
LOW
119.10
VOLUME
267.35K
TURNOVER
0
52 WEEK HIGH
151.18
52 WEEK LOW
18.23
MARKET CAP
1.72B
P/E (TTM)
-32.3282
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PVLA last week (0330-0403)?
Weekly Report · 1d ago
Analysts Offer Insights on Healthcare Companies: Tilray (TLRY), Immunovant (IMVT) and Palvella Therapeutics (PVLA)
TipRanks · 5d ago
Palvella Therapeutics Director Makes Bold New Insider Bet
TipRanks · 5d ago
Palvella director George M. Jenkins acquires PVLA shares worth 0.1 million
Reuters · 5d ago
Analysts Offer Insights on Healthcare Companies: Inventiva (IVA), MAIA Biotechnology, Inc. (MAIA) and Palvella Therapeutics (PVLA)
TipRanks · 5d ago
3 Best Stocks to Buy Today, 4/1/2026, According to Top Analysts
TipRanks · 6d ago
Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Insight Molecular Diagnostics (IMDX) and Delcath Systems (DCTH)
TipRanks · 6d ago
PALVELLA THERAPEUTICS INC <PVLA.O>: RAYMOND JAMES RAISES TARGET PRICE TO $225 FROM $193
Reuters · 6d ago
More
About PVLA
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. The Company is developing a pipeline of product candidates based on its patented QTORIN platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Its QTORIN product candidates are developed to accommodate the cargo at high concentrations in order to drive sufficient drug to its target deep in the epidermis and dermis. The Company's lead product candidate, QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin), is being evaluated in the Phase III SELVA clinical trial in microcystic lymphatic malformations and the Phase II TOIVA clinical trial in cutaneous venous malformations.

Webull offers Palvella Therapeutics Inc stock information, including NASDAQ: PVLA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PVLA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PVLA stock methods without spending real money on the virtual paper trading platform.